I am excited to share the news that I will join University of Pennsylvania as Assistant Professor in Cardio-Oncology in a month. Infinite thank you to @USFHealth & @MoffittNews and all my mentors and friends. Sad to leave, but full of nervous excitement for potential growth.

RT @avirupguha: 📢🧵Two back-to-back papers highlight a critical and overlooked issue in HR+/HER2– metastatic breast cancer (mBC): ⚠️cardiova….

RT @md_addison: Excited to finally see our #NIH R01 funded!. I am hopeful we can leverage #AI to help many #BreastCancer patients avoid #ca….

Two amazing papers on field of pHTN and MPNs written by none other than @LeivaOrly. I hope that pHTN be considered as a real risk factor and disease entity with clinical implications. Not just looking at LVEF during care of our cancer patients. @KuykendallMd @Ramikomrokji.

RT @NeilFlochMD: Increased risk of 13 different cancers with an elevated BMI @NEJM #obesity

RT @tangming2005: 🧵 1/ In high-dimensional bio data—transcriptomics, proteomics, metabolomics—you're almost guaranteed to find something “….

RT @LeivaOrly: 🔥New Pub @Haematologica 🔥 This was a multi-cntr study of #MPNsm with #echofirst from @nyugrossman & @MGHCancerCenter. We fo….

Mentor, friend, and collaborator. Don’t let the pink dress fool you! Tireless, hard-working and brilliant physician-scientists and mom at the same time… Sad that I will be saying good bye to them in a month. but collaboration will continue!!.

RT @ZhuoerXie: #Clone size matter! Sharing our manuscript at @Bloodneoplasia here ! .@MoffittNews.

RT @asnpublications: Research suggests Clonal hematopoiesis of indeterminate potential (CHIP) may contribute to CKD and its comorbidities.….

RT @NEJM: Both clonal hematopoiesis of indeterminate potential (CHIP) and cancer are more common with age. When they coexist in the same pa….

RT @CMichaelGibson: Lp(a) levels not associated with cardiovascular or all cause death when LDL and CRP adjusted for. Is Lp(a) just a mar….

RT @drbennisahmed: Efficacy and Safety of SGLT-2 Inhibitors in Patients With and Without Advanced CKD: Systematic Review and Meta-Analysis….

RT @KSusztak: Common-variant and rare-variant genetic architecture of heart failure across the allele-frequency spectrum | ⁦@NatureGenet⁩….

Cardiovascular care in patients with cancer is critical. Truly appreciate @AHAScience and #FDOH Florida Cancer Innovation Fund by @CaseyDeSantis for the opportunity to work on improving CV care in patients with cancer. More work to do! Thank you! (10/10 End).

Last but not least, thankful for @USFHealth @MoffittNews for allowing such study. Stronger than ever covalent bond relation between Cardiology/ Oncology Colleagues @mealomar. USF RISE office recommending stellar MS student Stefanie Palfi! (9/10).

CVAEs after CAR-T for MM are 1) relatively common, mostly arrhythmias 2) due to inflammation post CAR-T and 3) not driver of inferior survival early after CAR-T. Yet, diligent CRS management and cardiovascular monitoring and management crucial for our CAR-T patients. (8/10).

So. We believe that the acute systemic illness post CAR-T (infection, CRS) are the driver of inferior survival, rather than the CVAE being the root cause. In other words, CVAE is a byproduct of these systemic illnesses, rather than a driver of inferior survival. (7/10).

We stratified into myeloma-related death (cancer progression) vs. non-myeloma-related deaths (mostly infection, CRS). It was the non-MRDs that contributed to "early deaths", as expected. Importantly, CVAE did NOT affect incidence of death in non-MRD (Gray's test P=0.29) (6/10)

In univariate KM curve, CVAE "seems to have inferior survival". However, in MV analysis, presence of CVAE was not associated with inferior overall survival, after adjustment with covariates. There was a steep, early death (<1 month) in the CVAE group. Why? (5/10)